Werewolf Therapeutics, Inc. (HOWL) — SEC Filings
Werewolf Therapeutics, Inc. (HOWL) — 34 SEC filings. Latest: 10-Q (May 7, 2026). Includes 13 8-K, 7 10-Q, 5 SC 13G/A.
View Werewolf Therapeutics, Inc. on SEC EDGAR
Overview
Werewolf Therapeutics, Inc. (HOWL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 27, 2026: Werewolf Therapeutics, Inc. (HOWL) reported significant operational changes and clinical trial progress for the fiscal year ended December 31, 2025, while facing substantial doubt about its ability to continue as a going concern. The company initiated a strategic review process in February 2026, eng
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 5 bearish, 29 neutral. The dominant filing sentiment for Werewolf Therapeutics, Inc. is neutral.
Filing Type Overview
Werewolf Therapeutics, Inc. (HOWL) has filed 1 4, 7 10-Q, 3 10-K, 13 8-K, 2 DEF 14A, 5 SC 13G/A, 2 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of HOWL's 24 recent filings, 5 were flagged as high-risk, 8 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | Not Disclosed |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Dr. Rahul Chaturvedi
- Dr. David R. Boulware
- Ms. Sarah E. Kelly
- Peter Kolchinsky
- RAJEEV SHAH
- David Rosen
Industry Context
The biopharmaceutical industry, particularly in oncology, is highly competitive and innovation-driven. Companies are focused on developing novel immunotherapies and targeted treatments to address unmet medical needs. The landscape is characterized by significant R&D investment, long development timelines, and high regulatory hurdles. Emerging technologies like conditional activation and bispecific antibodies are gaining traction for their potential to improve efficacy and safety profiles.
Top Tags
Biotechnology (5) · 10-Q (4) · Oncology (3) · Clinical Trials (3) · biotech (3) · Going Concern (2) · Cash Burn (2) · Net Loss (2) · delisting (2) · listing-standards (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of common stock held by non-affiliates | $39,559,339 | as of June 30, 2025, indicating a relatively small market capitalization for a biotech company |
| Shares of common stock outstanding | 48,596,817 | as of March 20, 2026 |
| Workforce reduction | 64% | part of the restructuring plan to extend capital resources |
| Estimated one-time charge for employee separation benefits | $4.1 million | anticipated in Q1 2026 due to the reduction in force |
| Objective response rate for WTX-124 monotherapy | 21% | in heavily pretreated patients with advanced or metastatic cutaneous melanoma by December 2025 |
| Reduction in tumor target lesions for WTX-330 | 45% | in one confirmed partial response in metastatic gall bladder cancer by December 2025 |
| Net Loss (Q3 2025) | $16.37M | Slightly improved from $16.67M in Q3 2024, but still a significant loss. |
| Net Loss (YTD 2025) | $52.44M | Widened from $50.11M in YTD 2024, indicating increasing overall losses. |
| Collaboration Revenue (Q3 & YTD 2025) | $0 | A significant drop from $1.885M in YTD 2024, highlighting lack of external funding streams. |
| Cash & Cash Equivalents (Sept 30, 2025) | $65.71M | A substantial decrease from $110.99M at Dec 31, 2024, indicating rapid cash burn. |
| Net Cash Used in Operations (YTD 2025) | $49.27M | Increased from $41.94M in YTD 2024, accelerating the depletion of cash reserves. |
| Common Shares Outstanding (Oct 29, 2025) | 48,540,200 | Increased from 44,827,159 at Dec 31, 2024, suggesting potential dilution from capital raises. |
| R&D Expenses (Q3 2025) | $11.63M | Decreased from $12.53M in Q3 2024, potentially signaling a slowdown in development activities. |
| SEC File Number | 001-40366 | Identifies the company's filings with the SEC. |
| IRS Employer Identification No. | 82-3523180 | Company's tax identification number. |
Forward-Looking Statements
- {"claim":"Rubric Capital Management LP will maintain a significant stake in Werewolf Therapeutics, Inc. for the foreseeable future.","entity":"Rubric Capital Management LP","targetDate":"2025-12-31","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Werewolf Therapeutics, Inc. (HOWL)?
Werewolf Therapeutics, Inc. has 34 recent SEC filings from Jan 2024 to May 2026, including 13 8-K, 7 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HOWL filings?
Across 34 filings, the sentiment breakdown is: 5 bearish, 29 neutral. The dominant sentiment is neutral.
Where can I find Werewolf Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Werewolf Therapeutics, Inc. (HOWL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Werewolf Therapeutics, Inc.?
Key financial highlights from Werewolf Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HOWL?
The investment thesis for HOWL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Werewolf Therapeutics, Inc.?
Key executives identified across Werewolf Therapeutics, Inc.'s filings include Dr. Rahul Chaturvedi, Dr. David R. Boulware, Ms. Sarah E. Kelly, Peter Kolchinsky, RAJEEV SHAH and 1 others.
What are the main risk factors for Werewolf Therapeutics, Inc. stock?
Of HOWL's 24 assessed filings, 5 were flagged high-risk, 8 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Werewolf Therapeutics, Inc.?
Recent forward-looking statements from Werewolf Therapeutics, Inc. include guidance on {"claim":"Rubric Capital Management LP will maintain a significant stake in Werewolf Therapeutics, Inc. for the foreseea.